Double Bond Pharmaceutical (DBP) Q2 2026 earnings summary

Executive summary

• Ongoing negotiations with four potential partners, including two pharmaceutical companies and two financial investors, focused on Temodex and SI053 products.

• Preparing a supplementary cohort analysis based on MGMT status to strengthen RWE study evidence for Temodex.

• Active preparations for major medical congress presentations and commercialization of Temodex in Turkey, China, and Mexico.

Financial highlights

• Total revenue for Q2 2026 and H1 2026 was 0.0 MSEK, unchanged year-over-year.

• Operating loss for Q2 2026 was -0.6 MSEK (vs. -0.4 MSEK Q2 2025); H1 2026 operating loss was -0.9 MSEK (vs. -0.8 MSEK H1 2025).

• Net loss for Q2 2026 was -0.6 MSEK (vs. -0.4 MSEK Q2 2025); H1 2026 net loss was -0.9 MSEK (improved from -1.5 MSEK H1 2025).

• Earnings per share for H1 2026 was -0.00 SEK (vs. -0.02 SEK H1 2025).

• Cash and cash equivalents at June 30, 2026, were 239,519 SEK (vs. 255,067 SEK June 30, 2025).

Outlook and guidance

• Focus remains on advancing negotiations, completing the MGMT cohort analysis, maximizing congress presence, and commercializing Temodex in key markets.

• Next financial report scheduled for November 25, 2026.